TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com
by Scott Moore · The Cerbat GemStockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.
Check Out Our Latest Research Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Price Performance
NASDAQ:TCON opened at $0.11 on Friday. The stock’s fifty day moving average price is $0.12 and its two-hundred day moving average price is $1.45. The company has a market cap of $392,064.75, a P/E ratio of 0.17 and a beta of 1.36. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75.
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $0.06 million for the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Further Reading
- Five stocks we like better than TRACON Pharmaceuticals
- Consumer Staples Stocks, Explained
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- How to Read Stock Charts for Beginners
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Breakout Stocks: What They Are and How to Identify Them
- RPM International Thrives in Rate-Cut Driven Construction Rally